|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gillen S, Schuster T, Meyer Zum,
Büschenfelde C, Friess H and Kleeff J: Preoperative/neoadjuvant
therapy in pancreatic cancer: A systematic review and meta-analysis
of response and resection percentages. PLoS Med. 7:e10002672010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kamisawa T, Isawa T, Koike M, Tsuruta K
and Okamoto A: Hematogenous metastases of pancreatic ductal
carcinoma. Pancreas. 11:345–349. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gattinoni L, Klebanoff CA and Restifo NP:
Paths to stemness: Building the ultimate antitumour T cell. Nat Rev
Cancer. 12:671–684. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Magee JA, Piskounova E and Morrison SJ:
Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer
Cell. 21:283–296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Clevers H: The cancer stem cell: Premises,
promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sengupta S, Nagalingam A, Muniraj N,
Bonner MY, Mistriotis P, Afthinos A, Kuppusamy P, Lanoue D, Cho S,
Korangath P, et al: Activation of tumor suppressor LKB1 by honokiol
abrogates cancer stem-like phenotype in breast cancer via
inhibition of oncogenic Stat3. Oncogene. 36:5709–5721. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chaffer CL, Marjanovic ND, Lee T, Bell G,
Kleer CG, Reinhardt F, D’Alessio AC, Young RA and Weinberg RA:
Poised chromatin at the ZEB1 promoter enables breast cancer cell
plasticity and enhances tumorigenicity. Cell. 154:61–74. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abel EV and Simeone DM: Biology and
clinical applications of pancreatic cancer stem cells.
Gastroenterology. 144:1241–1248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hardie DG: AMP-activated/SNF1 protein
kinases: Conserved guardians of cellular energy. Nat Rev Mol Cell
Biol. 8:774–785. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Young LH, Li J, Baron SJ and Russell RR:
AMP-activated protein kinase: A key stress signaling pathway in the
heart. Trends Cardiovasc Med. 15:110–118. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zheng X, Chi J, Zhi J, Zhang H, Yue D,
Zhao J, Li D, Li Y, Gao M and Guo J: Aurora-A-mediated
phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to
facilitate NSCLC growth and migration. Oncogene. 37:502–511. 2018.
View Article : Google Scholar
|
|
16
|
Shi WY, Xiao D, Wang L, Dong LH, Yan ZX,
Shen ZX, Chen SJ, Chen Y and Zhao WL: Therapeutic metformin/AMPK
activation blocked lymphoma cell growth via inhibition of mTOR
pathway and induction of autophagy. Cell Death Dis. 3:e2752012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Handy JA, Saxena NK, Fu P, Lin S, Mells
JE, Gupta NA and Anania FA: Adiponectin activation of AMPK disrupts
leptin-mediated hepatic fibrosis via suppressors of cytokine
signaling (SOCS-3). J Cell Biochem. 110:1195–1207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
da Silva Morais A, Abarca-Quinones J,
Guigas B, Viollet B, Stärkel P, Horsmans Y and Leclercq IA:
Development of hepatic fibrosis occurs normally in AMPK-deficient
mice. Clin Sci (Lond). 118:411–420. 2009. View Article : Google Scholar
|
|
19
|
Kahn BB, Alquier T, Carling D and Hardie
DG: AMP-activated protein kinase: Ancient energy gauge provides
clues to modern understanding of metabolism. Cell Metab. 1:15–25.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Menendez JA, Joven J, Cufí S,
Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Martin-Castillo B,
López-Bonet E, Alarcón T and Vazquez-Martin A: The Warburg effect
version 2.0: Metabolic reprogramming of cancer stem cells. Cell
Cycle. 12:1166–1179. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheng X, Kim JY, Ghafoory S, Duvaci T,
Rafiee R, Theobald J, Alborzinia H, Holenya P, Fredebohm J, Merz
KH, et al: Methylisoindigo preferentially kills cancer stem cells
by interfering cell metabolism via inhibition of LKB1 and
activation of AMPK in PDACs. Mol Oncol. 10:806–824. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lonardo E, Cioffi M, Sancho P,
Sanchez-Ripoll Y, Trabulo SM, Dorado J, Balic A, Hidalgo M and
Heeschen C: Metformin targets the metabolic achilles heel of human
pancreatic cancer stem cells. PLoS One. 8:e765182013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bao B, Wang Z, Ali S, Ahmad A, Azmi AS,
Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S, et al: Metformin
inhibits cell proliferation, migration and invasion by attenuating
CSC function mediated by deregulating miRNAs in pancreatic cancer
cells. Cancer Prev Res (Phila). 5:355–364. 2012. View Article : Google Scholar
|
|
24
|
Machado DG, Cunha MP, Neis VB, Balen GO,
Colla A, Bettio LE, Oliveira A, Pazini FL, Dalmarco JB, Simionatto
EL, et al: Antidepressant-like effects of fractions, essential oil,
carnosol and betulinic acid isolated from Rosmarinus officinalis L.
Food Chem. 136:999–1005. 2013. View Article : Google Scholar
|
|
25
|
Tsai JC, Peng WH, Chiu TH, Lai SC and Lee
CY: Anti-inflammatory effects of Scoparia dulcis L. and betulinic
acid. Am J Chin Med. 39:943–956. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Viji V, Helen A and Luxmi VR: Betulinic
acid inhibits endotoxin-stimulated phosphorylation cascade and
pro-inflammatory prostaglandin E(2) production in human peripheral
blood mononuclear cells. Br J Pharmacol. 162:1291–1303. 2011.
View Article : Google Scholar :
|
|
27
|
Qian K, Bori ID, Chen CH, Huang L and Lee
KH: Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as
potent HIV maturation inhibitors. J Med Chem. 55:8128–8136. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fujioka T, Kashiwada Y, Kilkuskie RE,
Cosentino LM, Ballas LM, Jiang JB, Janzen WP, Chen IS and Lee KH:
Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV
principles from Syzigium claviflorum, and the anti-HIV activity of
structurally related triterpenoids. J Nat Prod. 57:243–247. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jain M, Kapadia R, Jadeja RN, Thounaojam
MC, Devkar RV and Mishra SH: Hepatoprotective potential of
Tecomella undulata stem bark is partially due to the presence of
betulinic acid. J Ethnopharmacol. 143:194–200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang P, Li Q, Li K, Zhang X, Han Z, Wang
J, Gao D and Li J: Betulinic acid exerts immunoregulation and
anti-tumor effect on cervical carcinoma (U14) tumor-bearing mice.
Pharmazie. 67:733–739. 2012.PubMed/NCBI
|
|
31
|
Liu Y and Luo W: Betulinic acid induces
Bax/Bak-independent cytochrome c release in human nasopharyngeal
carcinoma cells. Mol Cells. 33:517–524. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chintharlapalli S, Papineni S, Lei P,
Pathi S and Safe S: Betulinic acid inhibits colon cancer cell and
tumor growth and induces proteasome-dependent and -independent
downregulation of specificity proteins (Sp) transcription factors.
BMC Cancer. 11:3712011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gao Y, Jia Z, Kong X, Li Q, Chang DZ, Wei
D, Le X, Suyun H, Huang S, Wang L, et al: Combining betulinic acid
and mithramycin a effectively suppresses pancreatic cancer by
inhibiting proliferation, invasion, and angiogenesis. Cancer Res.
71:5182–5193. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li L, Du Y, Kong X, Li Z, Jia Z, Cui J,
Gao J, Wang G and Xie K: Lamin B1 is a novel therapeutic target of
betulinic acid in pancreatic cancer. Clinical Cancer Res.
19:4651–4661. 2013. View Article : Google Scholar
|
|
35
|
Quan HY, Kim DY, Kim SJ, Jo HK, Kim GW and
Chung SH: Betulinic acid alleviates non-alcoholic fatty liver by
inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling
pathway. Biochem Pharmacol. 85:1330–1340. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ma J, Duan W, Han S, Lei J, Xu Q, Chen X,
Jiang Z, Nan L, Li J, Chen K, et al: Ginkgolic acid suppresses the
development of pancreatic cancer by inhibiting pathways driving
lipogenesis. Oncotarget. 6:20993–21003. 2015.PubMed/NCBI
|
|
37
|
Lei J, Ma J, Ma Q, Li X, Liu H, Xu Q, Duan
W, Sun Q, Xu J, Wu Z, et al: Hedgehog signaling regulates hypoxia
induced epithelial to mesenchymal transition and invasion in
pancreatic cancer cells via a ligand-independent manner. Mol
Cancer. 12:662013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lei J, Huo X, Duan W, Xu Q, Li R, Ma J, Li
X, Han L, Li W, Sun H, et al: α-Mangostin inhibits hypoxia-driven
ROS-induced PSC activation and pancreatic cancer cell invasion.
Cancer Lett. 347:129–138. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Özdemir BC, Pentcheva-Hoang T, Carstens
JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C,
Novitskiy SV, et al: Depletion of carcinoma-associated fibroblasts
and fibrosis induces immunosuppression and accelerates pancreas
cancer with reduced survival. Cancer Cell. 25:719–734. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Duan W, Chen K, Jiang Z, Chen X, Sun L, Li
J, Lei J, Xu Q, Ma J, Li X, et al: Desmoplasia suppression by
metformin-mediated AMPK activation inhibits pancreatic cancer
progression. Cancer Lett. 385:225–233. 2017. View Article : Google Scholar
|
|
42
|
Chen K, Qian W, Li J, Jiang Z, Cheng L,
Yan B, Cao J, Sun L, Zhou C, Lei M, et al: Loss of AMPK activation
promotes the invasion and metastasis of pancreatic cancer through
an HSF1-dependent pathway. Mol Oncol. 11:1475–1492. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Thiery JP: Epithelial-mesenchymal
transitions in development and pathologies. Curr Opin Cell Biol.
15:740–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Corominas-Faja B, Cufí S,
Oliveras-Ferraros C, Cuyàs E, López-Bonet E, Lupu R, Alarcón T,
Vellon L, Iglesias JM, Leis O, et al: Nuclear reprogramming of
luminal-like breast cancer cells generates Sox2-overexpressing
cancer stem-like cellular states harboring transcriptional
activation of the mTOR pathway. Cell Cycle. 12:3109–3124. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang Z, Duan Q, Zhao H, Liu T, Wu H, Shen
Q, Wang C and Yin T: Gemcitabine treatment promotes pancreatic
cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.
Cancer Lett. 382:53–63. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cao J, Yang J, Ramachandran V, Arumugam T,
Deng D, Li Z, Xu L and Logsdon CD: TM4SF1 promotes gemcitabine
resistance of pancreatic cancer in vitro and in vivo. PLoS One.
10:e01449692015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhao J, Li J, Schlößer HA, Popp F, Popp
MC, Alakus H, Jauch KW, Bruns CJ and Zhao Y: Targeting cancer stem
cells and their Niche: Current therapeutic implications and
challenges in pancreatic cancer. Stem Cells Int.
2017.6012810:2017.
|
|
49
|
Kondo M, Wagers AJ, Manz MG, Prohaska SS,
Scherer DC, Beilhack GF, Shizuru JA and Weissman IL: Biology of
hematopoietic stem cells and progenitors: Implications for clinical
application. Annu Rev Immunol. 21:759–806. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ben-Porath I, Thomson MW, Carey VJ, Ge R,
Bell GW, Regev A and Weinberg RA: An embryonic stem cell-like gene
expression signature in poorly differentiated aggressive human
tumors. Nat Genet. 40:499–507. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
51
|
Faubert B, Boily G, Izreig S, Griss T,
Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, et
al: AMPK is a negative regulator of the Warburg effect and
suppresses tumor growth in vivo. Cell Metab. 17:113–124. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Vazquez-Martin A, Vellon L, Quirós PM,
Cufí S, Ruiz de Galarreta E, Oliveras-Ferraros C, Martin AG,
Martin-Castillo B, López-Otín C and Menendez JA: Activation of
AMP-activated protein kinase (AMPK) provides a metabolic barrier to
reprogramming somatic cells into stem cells. Cell Cycle.
11:974–989. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang L, Dong P, Wang W, Huang M and Tian
B: Gemcitabine treatment causes resistance and malignancy of
pancreatic cancer stem-like cells via induction of lncRNA HOTAIR.
Exp Ther Med. 14:4773–4780. 2017.PubMed/NCBI
|
|
54
|
Pisha E, Chai H, Lee IS, Chagwedera TE,
Farnsworth NR, Cordell GA, Beecher CW, Fong HH, Kinghorn AD, Brown
DM, et al: Discovery of betulinic acid as a selective inhibitor of
human melanoma that functions by induction of apoptosis. Nat Med.
1:1046–1051. 1995. View Article : Google Scholar : PubMed/NCBI
|
